All articles tagged with #biotech acquisition
Novo Nordisk has made an unsolicited bid to acquire obesity-focused biotech Metsera, aiming to outbid Pfizer, which had previously announced its plan to purchase the firm. The move has sparked a bidding war in the competitive obesity market, with Metsera indicating it considers Novo's offer superior and giving Pfizer a deadline to renegotiate.
Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion to expand into in vivo CAR-T cell therapies, focusing on autoimmune diseases and leveraging Orbital's RNA-based approach to produce CAR-T cells within the body, marking a significant move in the biotech and cell therapy markets.
Eli Lilly is in advanced negotiations to acquire Verve Therapeutics for up to $1.3 billion, aiming to expand its pipeline with gene-editing therapies, particularly targeting cholesterol treatment, in a strategic move during a period of cautious dealmaking in the pharma industry.
Eli Lilly is expanding its presence in the non-opioid pain treatment market by acquiring California biotech SiteOne Therapeutics for up to $1 billion.